Dr. Craig Eagle, MD, Chief Medical Officer at Guardant Health discusses a new study published in “Nature Medicine” which demonstrated that using the Guardant360 liquid biopsy test can help guide treatment decisions for patients with HER2-driven metastatic colorectal cancer (mCRC). The Phase 2 study – TRastuzumab combIned with pertuzUMab for patients with Her2-positive mCRC (TRIUMPH) – showed that the Guardant360 test can select patients for HER2-directed therapy, identify which patients are responding to treatment, as well as identify genetic alterations that predict resistance.
Dr. Craig Eagle currently serves as Guardant Health’s Chief Medical Officer. Prior to joining Guardant Health, Dr. Eagle has most recently served as Vice President of Medical Affairs Oncology for Genentech where he oversaw the medical programs across the oncology portfolio and developed innovative cancer trials and strategies in personalized health care.
Prior to Genentech, Dr. Eagle has held several positions in the U.S. and internationally over his 19-year career at Pfizer including global head of the Oncology Medical and Outcomes Group. In this role, he oversaw the worldwide medical programs and development of numerous commercially successful drugs. Dr. Eagle currently serves on the Board of Directors for Generex Biotechnology and NuGenerex Immuno-Oncology.
Dr. Eagle attended medical school at the University of New South Wales in Sydney, Australia and received his general internist training at Royal North Shore Hospital in Sydney. Dr. Eagle completed his specialist training in hemato-oncology and laboratory hematology at Royal Prince Alfred Hospital in Sydney and was granted Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists Australasia (FRCPA).